GlaxoSmithKline Plc - Digital Transformation Strategies

GlaxoSmithKline Plc - Digital Transformation Strategies

Summary

GlaxoSmithKline Plc (GSK) is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide.

In December 2021, GSK and the University of Oxford has entered five-year collaboration to establish Oxford-GSK Institute. The institute aims to improve the success and speed of research and development of new medicines, by building on insights from human genetics and using advanced technologies such as functional genomics and machine learning.

The report provides information and insights into GlaxoSmithKline's tech activities, including -

• Insights of its digital transformation strategies and innovation programs
• Overview of technology initiatives covering partnerships, product launches and investments
• Insights on each technology initiative including technology theme, objective, and benefits
• Details of estimated ICT budgets and major ICT contracts

Scope

• GSK uses artificial intelligence (AI) and machine learning (ML) to integrate population-scale datasets and observational cohorts with complex models to transform drug discovery. This process enables GSK’s scientists to quickly and accurately identify genetic variants linked to diseases..
• GSK is innovating in vaccine development by employing a 'digital twin,' a real-time simulation of the entire vaccine manufacturing process. In this closed-loop system, there is a constant exchange of insights between the real and virtual realms, which enables scientists to optimize the production process.
• The GSK Onyx Research Data Platform is a technology-driven initiative aimed at using data to discover treatments more efficiently. Onyx encompasses a suite of cutting-edge platforms designed to process and leverage vast amounts of data generated.
• In 2023, GSK India collaborated with PadUp Ventures for Hello Tomorrow, an educational boot camp for healthcare startups aiming to support innovative solutions and present graduating startups to the GSK India Leadership Team.

Reasons to Buy

• Gain insights into GSK's tech operations.
• Gain insights into its tech strategies and innovation initiatives.
• Gain insights into its technology themes under focus.
• Gain insights into various product launches, partnerships and investment strategies.